Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | IKBKB | O14920 | 2/20 | 0.63 |
| ▸ | CHUK | O15111 | 2/20 | 0.63 |
| ▸ | IKBKG | Q9Y6K9 | 2/20 | 0.63 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | STAT1 | P42224 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.60 |
| ▸ | SNCA | P37840 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028001 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| O,O'-Dimethylcaffeic Acid SCHEMBL81317 | 0.86 | KDM4E (1.00) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| O,O'-Dimethylcaffeic Acid SCHEMBL29636389 | 0.86 | KDM4E (1.00) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| O,O'-Dimethylcaffeic Acid SCHEMBL81318 | 0.86 | KDM4E (1.00) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL9972294 | 0.86 | SMN1; SMN2 (0.69) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| O,O'-Dimethylcaffeic Acid SCHEMBL28025225 | 0.85 | KDM4E (0.97) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| O,O'-Dimethylcaffeic Acid SCHEMBL27858762 | 0.85 | KDM4E (0.97) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| O,O'-Dimethylcaffeic Acid SCHEMBL27858763 | 0.85 | KDM4E (0.97) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL16621556 | 0.84 | JUN (0.80) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL30493821 | 0.84 | NFKB1 (0.79) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585266-A2 | COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2025-07-16 | — | — | EP | disclosed |
| EP-3882244-B1 | COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RES INST CHEMICAL TECH (KR) | 2025-03-05 | — | — | EP | disclosed |
| EP-3882244-A1 | COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2021-09-22 | — | — | EP | disclosed |
| EP-2933254-B1 | NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RES INST CHEMICAL TECH (KR) | 2021-01-20 | — | — | EP | disclosed |
| US-9951058-B2 | Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) | 2018-04-24 | — | — | US | disclosed |
| US-9790197-B2 | Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) | 2017-10-17 | — | — | US | disclosed |
| US-20170158684-A1 | NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2017-06-08 | — | — | US | disclosed |
| US-20150336920-A1 | NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-11-26 | — | — | US | disclosed |
| EP-2933254-A1 | NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2015-10-21 | — | — | EP | disclosed |
| EP-0889884-B1 | 1,2,4-TRIAZINE DERIVATIVES FOR THE INHIBITION OF PROTEIN GLYCOSYLATION | ALTEON INC (US) | 2003-01-29 | — | — | EP | disclosed |
| US-6380192-B1 | FOR INHIBITING NONENZYMATIC CROSS-LINKING (PROTEIN AGING) | ALTEON, INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6060470-A | Triazine compounds and methods of use therefor | ALTEON, INC. | 2000-05-09 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5932578-A | CAPABLE OF INHIBITING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS OF TARGET PROTEINS. FOOD SPOILAGE AND ANIMAL PROTEIN AGING CAN BE TREATED. | ALTEON INC. (US) | 1999-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158684-A1 | NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | RNASE1, HTRA1, IAPP | SMN1; SMN2 7/4885KDM4E 4532/4885ALDH1A1 2687/4885 |
| US-20150336920-A1 | NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | RNASE1, HTRA1, IAPP | SMN1; SMN2 7/4885KDM4E 4532/4885ALDH1A1 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.